CRISPR/Cas9 as precision and high-throughput genetic engineering tools in gastrointestinal cancer research and therapy
- PMID: 36372102
- DOI: 10.1016/j.ijbiomac.2022.11.018
CRISPR/Cas9 as precision and high-throughput genetic engineering tools in gastrointestinal cancer research and therapy
Abstract
Gastrointestinal cancer (GI) is one of the most serious and health-threatening diseases worldwide. Many countries have encountered an escalating prevalence of shock. Therefore, there is a pressing need to clarify the molecular pathogenesis of these cancers. The use of high-throughput technologies that allow the precise and simultaneous investigation of thousands of genes, proteins, and metabolites is a critical step in disease diagnosis and cure. Recent innovations have provided easy and reliable methods for genome investigation, including TALENs, ZFNs, and the CRISPR/Cas9 (clustered regularly interspaced palindromic repeats system). Among these, CRISPR/Cas9 has been revolutionary tool in genetic research. Recent years were prosperous years for CRISPR by the discovery of novel Cas enzymes, the Nobel Prize, and the development of critical clinical trials. This technology utilizes comprehensive information on genes associated with tumor development, provides high-throughput libraries for tumor therapy by developing screening platforms, and generates rapid tools for cancer therapy. This review discusses the various applications of CRISPR/Cas9 in genome editing, with a particular focus on genome manipulation, including infection-related genes, RNAi targets, pooled library screening for identification of unknown driver mutations, and molecular targets for gastrointestinal cancer modeling. Finally, it provides an overview of CRISPR/Cas9 clinical trials, as well as the challenges associated with its use.
Keywords: CRISPR/Cas9; Gastrointestinal cancers; Genetic engineering; Infectious diseases; Non-coding RNA; Organoid cancer modeling.
Copyright © 2022. Published by Elsevier B.V.
Conflict of interest statement
Declaration of competing interest This paper has been read and approved by all the authors and all of them declared no conflicts of interest.
Similar articles
-
Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.AIDS Rev. 2017 Oct-Dec;19(3):167-172. AIDS Rev. 2017. PMID: 29019352
-
CRISPR-Cas9 and CRISPR-Assisted Cytidine Deaminase Enable Precise and Efficient Genome Editing in Klebsiella pneumoniae.Appl Environ Microbiol. 2018 Nov 15;84(23):e01834-18. doi: 10.1128/AEM.01834-18. Print 2018 Dec 1. Appl Environ Microbiol. 2018. PMID: 30217854 Free PMC article.
-
CRISPR/Cas9 Platforms for Genome Editing in Plants: Developments and Applications.Mol Plant. 2016 Jul 6;9(7):961-74. doi: 10.1016/j.molp.2016.04.009. Epub 2016 Apr 20. Mol Plant. 2016. PMID: 27108381 Review.
-
CRISPR/Cas9: an advanced tool for editing plant genomes.Transgenic Res. 2016 Oct;25(5):561-73. doi: 10.1007/s11248-016-9953-5. Epub 2016 Mar 24. Transgenic Res. 2016. PMID: 27012546 Review.
-
Precision genome editing in plants: state-of-the-art in CRISPR/Cas9-based genome engineering.BMC Plant Biol. 2020 May 25;20(1):234. doi: 10.1186/s12870-020-02385-5. BMC Plant Biol. 2020. PMID: 32450802 Free PMC article. Review.
Cited by
-
CRISPR technology in human diseases.MedComm (2020). 2024 Jul 29;5(8):e672. doi: 10.1002/mco2.672. eCollection 2024 Aug. MedComm (2020). 2024. PMID: 39081515 Free PMC article. Review.
-
Cell death pathways: molecular mechanisms and therapeutic targets for cancer.MedComm (2020). 2024 Sep 4;5(9):e693. doi: 10.1002/mco2.693. eCollection 2024 Sep. MedComm (2020). 2024. PMID: 39239068 Free PMC article. Review.
-
Intelligent berberine-loaded erythrocytes attenuated inflammatory cytokine productions in macrophages.Sci Rep. 2024 Apr 23;14(1):9381. doi: 10.1038/s41598-024-60103-9. Sci Rep. 2024. PMID: 38654085 Free PMC article.
-
Identification of Novel lncRNAs Related to Colorectal Cancer Through Bioinformatics Analysis.Biomed Res Int. 2025 Jan 29;2025:5538575. doi: 10.1155/bmri/5538575. eCollection 2025. Biomed Res Int. 2025. PMID: 39949372 Free PMC article.
-
Tumor biomarkers for diagnosis, prognosis and targeted therapy.Signal Transduct Target Ther. 2024 May 20;9(1):132. doi: 10.1038/s41392-024-01823-2. Signal Transduct Target Ther. 2024. PMID: 38763973 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources